Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Maintenance Therapy in Patients with FLT3 -ITD-Mutation-Positive Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation: Real-World Survival

Hongbo Yang, Yan Song, James D. Griffin, Manasee V. Shah, Jonathan Freimark, Andrew Chilelli

Blood (2021) 138 (Supplement 1): 693.

https://doi.org/10.1182/blood-2021-145790

Published: 2021

Journal Articles

Patient and Physician Preferences for Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Patients Not Candidates for Intensive Chemotherapy

Mo Zhou, Hongbo Yang, Yan Song, Deborah A. Marshall, James D. Griffin, Lalit Saini, Manasee V. Shah

Blood (2021) 138 (Supplement 1): 4047.

https://doi.org/10.1182/blood-2021-145385

Published: 2021

Journal Articles

Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML)

Sophia Adamia, PhD, Sigitas J Verselis, PhD, Teru Hideshima, MD PhD, Michael P. Chu, MD, Shruti Bhatt, PhD, David P. Steensma, MD, Daniel J Deangelo, Richard M. Stone, MD, Daniel G. Tenen, MD, Linda M. Pilarski, PhD, James D. Griffin, MD, Kenneth Anderson, MD

Blood (2018) 132 (Supplement 1): 3895.

https://doi.org/10.1182/blood-2018-99-118501

Published: 2018

Journal Articles

Treatment Patterns and Healthcare Resource Utilization in Patients with Relapsed/Refractory Acute Myeloid Leukemia and a Subset with IDH1-Mutation: A United States Medical Chart Review Study

James D. Griffin, MD, Mike Storm, MSc, Ken Wilhelm, MD, Audra Boscoe, PhD, Dendy Macaulay, PhD, Zheng-Yi Zhou, PhD, Elizabeth Faust, MBA/MPH, Claudia Cheung, MS

Blood (2018) 132 (Supplement 1): 5864.

https://doi.org/10.1182/blood-2018-99-116495

Published: 2018

Journal Articles

Treatment Patterns and Healthcare Resource Utilization (HRU) in Patients with Relapsed/Refractory (R/R) FLT3 -Mutated ( FLT3 mut ) and FLT3 -Wild Type ( FLT3 wt ) Acute Myeloid Leukemia (AML): A Multi-Country Medical Chart Study

James D. Griffin, MD, Manasee V Shah, MPH, Yan Song, PhD, Hongbo Yang, PhD

Blood (2018) 132 (Supplement 1): 4824.

https://doi.org/10.1182/blood-2018-99-110871

Published: 2018

Journal Articles

Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-Mut and FLT3-Wt Acute Myeloid Leukemia: A Multi-Country Medical Chart Study

James D. Griffin, MD, Hongbo Yang, PhD, Yan Song, PhD, David Kinrich, BSE, Cat N. Bui, PhD

Blood (2017) 130 (Supplement 1): 2186.

https://doi.org/10.1182/blood.V130.Suppl_1.2186.2186

Published: 2017

Journal Articles

FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML)

Sophia Adamia, PhD, Jeffrey Nemeth, PhD, Shruti Bhatt, PhD, Sarah R Walker, Natalie I Voeks, William Lento, PhD, Ricardo M. Attar, Ilene Galinsky, MSN, ANPc, David A Frank, MD PhD, Martha Wadleigh, MD, Anthony Letai, MD PhD, David P. Steensma, MD, David M. Weinstock, MD, Daniel J. DeAngelo, MD PhD, David M. Dorfman, MD PhD, Richard M. Stone, MD, James D Griffin, MD

Blood (2016) 128 (22): 1681.

https://doi.org/10.1182/blood.V128.22.1681.1681

Published: 2016

Journal Articles

Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia

Sara Buhrlage, PhD, Ellen Weisberg, MD, Nathan Schauer, Jing Yang, PhD, Ilaria Lamberto, PhD, Laura Doherty, Atsushi Nonami, MDPhD, Amanda L. Christie, BS, David M. Weinstock, MD, Richard M. Stone, MD, Nathanael Gray, PhD, James D Griffin, MD

Blood (2016) 128 (22): 524.

https://doi.org/10.1182/blood.V128.22.524.524

Published: 2016

Journal Articles

Blood ’s 70th anniversary: arsenic—from poison pill to magic bullet

James D. Griffin

Blood (2016) 127 (14): 1729–1730.

https://doi.org/10.1182/blood-2015-10-638650

Published: 2016

Journal Articles

Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia

Pilar De La Puente, PhD, Ellen Weisberg, MD, Atsushi Nonami, MDPhD, Micah John Luderer, BS, MS, Richard M. Stone, MD, Junia V. Melo, MD PhD, James D Griffin, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 3694.

https://doi.org/10.1182/blood.V126.23.3694.3694

Published: 2015

Journal Articles

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach

Atsushi Nonami, Martin Sattler, Ellen Weisberg, Qingsong Liu, Jianming Zhang, Matthew P. Patricelli, Amanda L. Christie, Amy M. Saur, Nancy E. Kohl, Andrew L. Kung, Hojong Yoon, Taebo Sim, Nathanael S. Gray, James D. Griffin

Blood (2015) 125 (20): 3133–3143.

https://doi.org/10.1182/blood-2014-12-615906

Published: 2015

Includes: Supplemental data

Journal Articles

Identification of Wee1 and IGF-1R As Novel Therapeutic Targets for Mutant RAS-Driven Acute Leukemia By Combinatory Chemical Screens

Atsushi Nonami, MDPhD, Chen Zhao, PhD, Liu Qingsong, PhD, Kristen Cowens, Amanda L. Christie, Yongfei Chen, Martin Sattler, PhD, Kwok-Kin Wang, MDPhD, Nathanael S. Gray, PhD, James D. Griffin, MD, Ellen L. Weisberg, PhD

Blood (2014) 124 (21): 3502.

https://doi.org/10.1182/blood.V124.21.3502.3502

Published: 2014

Journal Articles

IDH1 Splicing Alterations in Patients with AML and Their Relationship to Blood 2HG Levels

Sophia Adamia, PhD, Patricia Toniolo, PhDcandidate, Amir T. Fathi, MD, Ilene Galinsky, ANP, Suiyang Liu, Katharine Yen, Hyeryun Kim Kim, Dongwei Zhu, Straley Kim, Martha Wadleigh, MD, David P. Steensma, MD, Ibiayi Dagogo-Jack, MD, Daniel J. DeAngelo, MD PhD, James D. Griffin, MD, Richard M. Stone, MD

Blood (2014) 124 (21): 1060.

https://doi.org/10.1182/blood.V124.21.1060.1060

Published: 2014

Journal Articles

NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML

Blood (2014) 123 (18): 2816–2825.

https://doi.org/10.1182/blood-2013-02-481507

Published: 2014

Includes: Supplemental data

Journal Articles

Aberrant Splicing In Patients With AML Is Associated With Over- Expression Of Specific Splicing Factors

Sophia Adamia, PhD, Christian Bach, Ph.D., Patrick M Pilarski, Martha Wadleigh, MD, David P. Steensma, MD, Gabriela Motyckova, MD, PhD, Daniel J. DeAngelo, MD, Ph.D, Richard M. Stone, MD, Daniel G. Tenen, MD, James D. Griffin, MD

Blood (2013) 122 (21): 3749.

https://doi.org/10.1182/blood.V122.21.3749.3749

Published: 2013

Journal Articles

Using Small Molecules To Identify Critical Signaling Pathways Of Mutant N-RAS In Acute Leukemia Cells

Atsushi Nonami, MD, PhD, Martin Sattler, PhD, Ellen L. Weisberg, PhD, Jianming Zhang, PhD, Qingsong Liu, PhD, Matthew Patricell, PhD, Hojong Yoon, Amanda L. Christie, B.S., Amy M. Sauer, Nancy Kohl, PhD, Andrew L. Kung, MD, PhD, Taebo Sim, PhD, Nathanael S. Gray, PhD, James D. Griffin, MD

Blood (2013) 122 (21): 169.

https://doi.org/10.1182/blood.V122.21.169.169

Published: 2013

Journal Articles

Small Molecule Activators Of AMPK Block The Glycogen Production Required For Transformation Of Myeloid Leukemia Cells

Haymanti Bhanot, PhD, Mamatha M. Reddy, PhD, Atsushi Nonami, MD, PhD, Ellen L. Weisberg, PhD, Kelly Xing, Sabrina K. Salgia, John M. Asara, PhD, Richard M. Stone, MD, James D. Griffin, MD, Martin Sattler, PhD

Blood (2013) 122 (21): 1479.

https://doi.org/10.1182/blood.V122.21.1479.1479

Published: 2013

Journal Articles

BCR-ABL Transformation Requires Glycogen Synthase 1 (GYS1) Expression for Cell Growth and Increased Glycogen Production

Mamatha M. Reddy, PhD, Anagha Deshpande, PhD, Atsushi Nonami, MD, PhD, Ellen L. Weisberg, PhD, Tirumala K. Chowdary, PhD, James D. Griffin, MD, Martin Sattler, PhD

Blood (2012) 120 (21): 1673.

https://doi.org/10.1182/blood.V120.21.1673.1673

Published: 2012

Journal Articles

Deciphering the Critical Pathways of Mutant N-RAS in AML Using Small Molecule Inhibitors.

Atsushi Nonami, MD, PhD, Martin Sattler, PhD, Ellen L. Weisberg, PhD, Liu Qingsong, PhD, Jianming Zhang, PhD, Guillaume Adelmant, PhD, Jarrod A Marto, PhD, Nancy Kohl, PhD, Andrew L. Kung, MD, PhD, Taebo Sim, PhD, Nathanael S Gray, PhD, James D. Griffin, MD

Blood (2012) 120 (21): 2455.

https://doi.org/10.1182/blood.V120.21.2455.2455

Published: 2012

Journal Articles

Comparison of Disease Outcomes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy.

James D. Griffin, MD, Annie Guerin, MSc, Lei Chen, MD, PhD, Alexander R. Macalalad, MD, Jiayuan Luo, MSc, Eric Qiong Wu, PhD

Blood (2012) 120 (21): 2796.

https://doi.org/10.1182/blood.V120.21.2796.2796

Published: 2012

NARROW

Maintenance Therapy in Patients with FLT3 -ITD-Mutation-Positive Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation: Real-World Survival

Patient and Physician Preferences for Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Patients Not Candidates for Intensive Chemotherapy

Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML)

Treatment Patterns and Healthcare Resource Utilization in Patients with Relapsed/Refractory Acute Myeloid Leukemia and a Subset with IDH1-Mutation: A United States Medical Chart Review Study

Treatment Patterns and Healthcare Resource Utilization (HRU) in Patients with Relapsed/Refractory (R/R) FLT3 -Mutated ( FLT3 mut ) and FLT3 -Wild Type ( FLT3 wt ) Acute Myeloid Leukemia (AML): A Multi-Country Medical Chart Study

Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-Mut and FLT3-Wt Acute Myeloid Leukemia: A Multi-Country Medical Chart Study

FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML)

Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia

Blood ’s 70th anniversary: arsenic—from poison pill to magic bullet

Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach

Identification of Wee1 and IGF-1R As Novel Therapeutic Targets for Mutant RAS-Driven Acute Leukemia By Combinatory Chemical Screens

IDH1 Splicing Alterations in Patients with AML and Their Relationship to Blood 2HG Levels

NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML

Aberrant Splicing In Patients With AML Is Associated With Over- Expression Of Specific Splicing Factors

Using Small Molecules To Identify Critical Signaling Pathways Of Mutant N-RAS In Acute Leukemia Cells

Small Molecule Activators Of AMPK Block The Glycogen Production Required For Transformation Of Myeloid Leukemia Cells

BCR-ABL Transformation Requires Glycogen Synthase 1 (GYS1) Expression for Cell Growth and Increased Glycogen Production

Deciphering the Critical Pathways of Mutant N-RAS in AML Using Small Molecule Inhibitors.

Comparison of Disease Outcomes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only